A pooled analysis showed Onglyza® (saxagliptin) provided improvements in key measures of blood sugar control in adults with Type 2 Diabetes at high risk for CV disease (Businesswire)
Diabetes News Service
Glycosmedia is also available as an App:
For iPhone and iPad | For Android devices
Sponsorship and Advertising
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
